If passed, TROA would: Permanently allow Medicare Part D to cover FDA-approved anti-obesity medications Expand Medicare Part B coverage of intensive behavioral therapy for obesity to include a wider range of providers (not just primary care physicians) However, in April 2025, CMS announced it would not include Medicare Part D coverage of obesity drugs in its rule changes for 2026, stating the proposal was "not appropriate at this time." That decision pushed the issue back to Congress, where the TROA remains under consideration
Retatrutide may eventually prove stronger, but its still in trials and not yet approved
Instead, its role is limited to the formulation itself, helping the peptide remain stable while stored in a vial
Is that worth it for Lilly and Novo to take their patents and sue in court
I have a few more to go and I know I will reach my goal
Possible weight loss after 17 weeks: Around 15 to 17% (over 68 weeks) Clinical trials have shown that patients taking Wegovy at the 2.4mg dose can lose around 15 to 17% of their body weight over 68 weeks [1]
